Press Releases

Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited (“Sigma”). The acquisition was approved following the extraordinary meeting of Sigma shareholders held on 14 January 2011. The effective date of change of ownership is 31 January 2011 and will position Aspen as the leading pharmaceutical company in Australia by volume of scripts generated. Stephen Saad, Aspen’s Group Chief Executive, said “Aspen is excited about this acquisition which enables the Group to accelerate growth in its Australian business and also to stimulate expansion plans into the broader Asia Pacific region. Aspen has already demonstrated its ability to supply high quality products at competitive prices across more than 100 worldwide territories. We have confidence in our Australian management team to leverage Aspen’s world-class procurement, manufacturing and distribution capabilities to ensure the expanded Aspen business delivers growing value in Australia.” In 2010 Aspen announced that it had reached a formal agreement to acquire Sigma’s pharmaceutical business on a debt-free basis for a cash consideration of AUD 900 million. The purchase consideration is approximately ZAR 6 148 million, based on an AUD/ZAR exchange rate of 0.1464 as at 13 January 2011. The transaction was however subject to a number of conditions precedent which have now been fulfilled. The Sigma business: Sigma, which has a 98-year legacy in Australia, is listed on the Australian Securities Exchange. Sigma’s pharmaceutical business, which is now being acquired by Aspen, consists of an extensive product portfolio of branded, generic and OTC products which include many well-known and trusted Australian brands as well as five manufacturing facilities. Sigma retains its wholesale business, and is one of three major wholesaler distributors in Australia. Aspen has concluded a long-term distribution agreement with Sigma. Rationale for the acquisition of Sigma’s pharmaceutical business: Aspen Australia, established in May 2001, markets and distributes pharmaceutical and consumer products. Aspen Australia has succeeded in delivering double-digit growth since inception as a greenfields operation in 2001, and recorded revenue of approximately AUD 180 million in the year ended 30 June 2010. Aspen Australia`s success has been achieved by sound management supported by an outstanding team which has consistently built Aspen`s branded product offering and reputation in Australia. Aspen Australia is currently ranked 7th in terms of volume of Australian scripts generated and its sales representative team has been voted number one in Australia. On the basis of this successful platform, the Sigma acquisition creates the following opportunities for Aspen: The extension of Aspen’s existing branded products business in Australia with the addition of Sigma’s branded, generics and OTC portfolios; An established point of entry into the Australian generics and OTC sectors for the introduction of Aspen`s pipeline of generic and OTC products; Securing a distribution channel for generic products through Sigma’s retained wholesale division; Providing additional opportunities to launch Aspen’s prolific product pipeline; Leveraging Aspen’s global manufacturing experience, expertise and capability through an Australian-based manufacturing presence; and Creating a foundation for further development of Aspen`s business in the Asia Pacific region. Based upon the historic performance of Aspen and Sigma in the Australian market, the combination of Sigma’s pharmaceutical business with Aspen’s existing business in Australia should lead to 1 in every 8 Australian prescriptions being written for an Aspen product and result in Aspen being ranked first by volume of scripts generated in Australia. Issued By: Shauneen Beukes, Shauneen Beukes Communication Tel: +27 12 661 8467; Cell: +27 82 389 8900 On Behalf of: Stephen Saad, Aspen Group Chief Executive Tel: +27 31 580 8601 Gus Attridge, Aspen Deputy Group Chief Executive Tel: +27 31 580 8602 Roshni Gajjar, Aspen Investor Relations Tel: +27 31 580 8649; Cell: +27 82 789 1826

Aspen ARV tender bid is successfulFollowing the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to announce that its South African operating company (Aspen) has been successful in winning a number of key products in the tender, including Efavirenz and Tenofovir, in spite of strong competition. The tender is effective for a period of two years, commencing 01 January 2011. Aspen secured more than 40% of the awarded tender value based upon expected future demand as published in the invitation to tender. The tender value is estimated to be R3.6 billion over 2 years. The South African ARV Tender is the largest of its kind in the world. Aspen has been a leading supplier to this tender since inception of the programme, providing a consistent and reliable supply of high-quality ARV products to the State. Aspen was awarded a share of the following products: Product/ % Awarded to Aspen Abacavir Solution 20mg/ml 40% Efavirenz Tablets 600mg 70% Lamivudine Scored Tablets 150mg 70% Nevirapine Tablets 200mg 40% Tenofovir Tablets 300g 70% Zidovudine Tablets 300mg 40% These tender results are further testament to Aspen’s cost competitiveness against both local and foreign suppliers. Aspen’s range of ARV’s are produced at its world-class manufacturing facilities in Port Elizabeth, South Africa. The Group has invested more than R2 billion over the last five years in extending its manufacturing capability and enhancing the existing facilities. This has resulted in unlocking capacity to accommodate growing demand from Aspen’s domestic and foreign territories and also contributed towards further optimising manufacturing efficiencies. In his response to the ARV Tender results, Aspen Group Chief Executive, Stephen Saad said: “These tender results confirm Aspen’s cost competitiveness and its credibility as a reliable supplier of pharmaceutical products. Aspen is proud to be able to contribute towards increasing access to affordable, high quality medicines in South Africa and thereby assist in the treatment of the HIV/AIDS pandemic.” Aspen’s portfolio of ARV’s supports close to 900 000 patients in South Africa daily. 14 December 2010 Sponsor: Investec Bank Limited Date: 14/12/2010 11:48:15 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.

By : Shauneen Beukes ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN ISIN: ZAE000066692 (“Aspen”) ANNOUNCEMENT REGARDING THE ACQUISITION OF THE PHARMACEUTICAL BUSINESS OF SIGMA PHARMACEUTICALS LIMITED (“SIGMA”) BY ASPEN 1. INTRODUCTION Aspen shareholders are referred to the detailed cautionary announcement released on the Securities Exchange News Service of the JSE Limited (“SENS”) on 21 May 2010, and to the related renewal and further cautionary announcements dated 7 July 2010 and 12 July 2010, respectively (“Cautionary Announcements”). Subsequent to the completion by Aspen of the due diligence process referred to in the Cautionary Announcements, Aspen Global Incorporated (“Aspen Global”), a 100% owned subsidiary of Aspen, submitted, to the Board of Directors of Sigma (“Sigma Board”), an offer (“Subsequent Offer”) to acquire the pharmaceutical business conducted by Sigma (“Pharmaceutical Business”) on a debt-free basis for a cash consideration of A$900 million (approximately ZAR5 871 million ). The Subsequent Offer, which the Sigma Board has undertaken to support, is subject to limited conditions precedent as detailed in paragraph 4.4 below. 2. DESCRIPTION OF SIGMA AND THE BUSINESS Sigma is a leading Australian Securities Exchange (“ASX”) listed Australian manufacturer and marketer of prescription, over-the-counter (“OTC”) and generic pharmaceutical products as well as a wholesale distributor of pharmaceutical and consumer products. The Pharmaceutical Business consists of the manufacture and marketing of pharmaceutical products. It has an extensive product portfolio comprising many well-known and trusted Australian brands which recorded sales revenue of A$671 million in the year to 31 January 2010. The generics range has approximately a 25% share of the growing Australian generics sector. The Pharmaceutical Business is also Australia’s largest pharmaceutical manufacturer. For further details on the Pharmaceutical Business, Aspen shareholders are referred to www.sigmaco.com.au. 3. RATIONALE FOR THE SUBSEQUENT OFFER Aspen has an existing operation in Australia (“Aspen Australia”), marketing and distributing pharmaceutical and consumer products. Established in 2001, Aspen Australia has an excellent record of growth with revenue of approximately A$180million recorded in the year to 30 June 2010. Aspen Australia’s success has been achieved by sound management supported by an outstanding team which has consistently built Aspen’s product offering and reputation in Australia. The implementation of the Subsequent Offer creates the following opportunities: Synergies arising out of the consolidation of Aspen Australia and the Pharmaceutical Business; An established point of entry to the Australian generics and OTC sectors for the introduction of Aspen’s pipeline of generic and OTC products; Strengthening Aspen’s position in the Australian market which will form the foundation for further development of Aspen’s business in the Asia Pacific region; and Incorporation of Australian manufacturing presence into Aspen’s global manufacturing capabilities. Aspen Global’s initial approach to Sigma referred to in the Cautionary Announcements was for the acquisition of the entire business of Sigma, including the wholesale business. The Subsequent Offer means that Sigma will continue as an ASX listed company focused on the wholesaling business. The construction of the Subsequent Offer was framed after lengthy engagement with Sigma and recognizes that Sigma possesses the critical skills to optimize the performance of the wholesaling business, an activity in which Aspen does not have past experience. Furthermore, the consideration received by Sigma for the Pharmaceutical Business will allow it to establish a firm capital base from which to ensure an efficient business model. In recognition of this, the Pharmaceutical Business will commit to a long term supply, distribution and logistics arrangement with Sigma. 4. DETAILS OF THE SUBSEQUENT OFFER 4.1 Terms of the Subsequent Offer In terms of the Subsequent Offer, Aspen Global, or an entity nominated by Aspen Global, will acquire the Pharmaceutical Business, by acquiring either the business conducted by the Pharmaceutical Business or the shares in the subsidiaries of Sigma that carry on the Pharmaceutical Business and/or hold assets of the Pharmaceutical Business, or a combination of the aforementioned, for a cash consideration of A$900 million (approximately ZAR5 871 million1) on a debt-free basis. In terms of the Subsequent Offer, Sigma, which has agreed to deal exclusively with Aspen until 15 October 2010, will also accept a non-compete clause with the Pharmaceutical Business for a period of two years. 4.2 Funding The Subsequent Offer will be funded out of Aspen’s available cash resources as well as cash to be raised from its bankers. 4.3 Effective date The effective date of the implementation of the Subsequent Offer will be upon completion of the conditions precedent. 4.4 Conditions precedent The completion of the Subsequent Offer is subject to the satisfactory conclusion of limited conditions precedent which are normal for a transaction of this nature, including: conclusion of a Business and/or Share Purchase Agreement between Aspen and Sigma; all requisite regulatory approvals; and the approval of Sigma shareholders. 5. PRO FORMA FINANCIAL EFFECTS The unaudited pro-forma financial effects set out in the table below have been prepared to assist Aspen shareholders to assess the impact of the Subsequent Offer on the earnings per share (“EPS”) and headline EPS (“HEPS”) for the 6 months ended 31 December 2009, and the net asset value (“NAV”) per Aspen ordinary share as at 31 December 2009. The pro-forma financial effects have been prepared for illustrative purposes only and because of their nature, may not fairly present the effects of the Subsequent Offer on Aspen’s results of operations for the 6 months ended and the financial position at 31 December 2009. The Pharmaceutical Business results used are for the 6 months ended 31 January 2010. The Directors of Aspen are responsible for the preparation of the financial effects, which have not been reviewed by the auditors. Pre-adjustment For the six months ended 31 December 2009 Post-adjustment For the six months ended 31 December 2009 Actual “Before” (cents) (1,3,8) Pro-forma “After” the Subsequent Offer (1,2,4,6,7) (cents) % Change2 Actual “Before” (cents) (1,3,8) Pro-forma “After” the Subsequent Offer (1,2,5,6,7) (cents) % Change2 EPS 240.58 (134.36) (155.8) 240.58 252.54 5.0 HEPS 242.32 (132.61) (154.7) 242.32 254.28 4.9 NAV 2,192.98 2,192.98 0.0 2,192.98 2,192.98 0.0 Notes: 1. Extracted from

Aspen Pharmacare Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN ISIN: ZAE000066692 (“Aspen”) Renewal of detailed cautionary announcement Aspen shareholders are referred to the detailed cautionary announcement dated 21 May 2010 and are advised that Aspen Global Incorporated (“Aspen Global”) has submitted to Sigma Pharmaceuticals Limited (“Sigma”), a confirmed offer to acquire the whole of Sigma (the “Transaction”) for cash at a price per Sigma share of A$0.55 (approx. ZAR3.58)1 (the “Offer”) which implies an equity value of A$648 million (approx. ZAR4 219 million)1 based on 1,178.6 million Sigma shares outstanding. Aspen has proposed that the Transaction be executed via a scheme of arrangement. The Offer is also subject to numerous conditions precedent, including the satisfactory completion by Aspen of a final due diligence investigation, the conclusion of a scheme implementation agreement and fulfillment of all necessary regulatory approvals. Aspen shareholders are referred to the announcement released today by Sigma, which is available at the ASX website www.asx.com.au. Accordingly, Aspen shareholders are advised to continue to exercise caution when dealing in Aspen shares until a further announcement is made. 1 Based on AUD/ZAR exchange rate of 0.1536 as at 7 July 2010 (Source: Bloomberg). Woodmead 7 July 2010

Aspen Pharmacare Holdings Limited (“Aspen”), listed on the JSE, South Africa (share code APN) and Strides Arcolab Limited, today announced a restructuring of their arrangements relating to the two oncology joint ventures (“JVs”) between Aspen and Strides, Onco Therapies Limited (“OTL”), India and Onco Laboratories Limited (“OLL”), Cyprus. The transactions The following are the material terms of the restructuring: a) Aspen Global Incorporated will sell its 50% ownership in the Oncology JVs to Strides for a consideration of USD 117 million; b) Strides will license the existing and future oncology products to Pharmacare Limited, an Aspen Group company, for certain territories; c) The effective date of the above transactions is the first day of the month following the fulfillment of the conditions precedent which include, inter alia, the approval of the Exchange Control Department of the Reserve Bank of South Africa; d) The payment terms are based upon certain future milestones with an outside date for settlement of all outstanding amounts by 30 April 2011. Rationale The transactions signal the strategic intent of Aspen and of Strides in the oncology market. The transactions compliment Aspen’s focus on sourcing differentiated products for supply through its international distribution network which reaches approximately 100 countries worldwide. Aspen already has a developing oncology business in most of these territories. Central to the Strides strategy is the enhancement of its manufacturing and development capabilities in its Specialties business. To this end, Strides has built capacities in facilities and development. This includes the establishment of world class sterile assets in India, Europe, the recent acquisition of the Campos facility in Brazil, and taking over full ownership of the Oncology JVs. The value of these assets has been demonstrated by the attraction of numerous leading pharmaceutical partners, including multinationals. Stephen Saad, Aspen Group Chief Executive said: “Through these agreements we continue to build on the strong partnership we enjoy with Strides. Each party now does what they do best. Our focus is commercialisation of these niche products in our territories. Aspen has and is building its own oncology product franchise. The existing and future pipeline of products from the Strides Group will be an important contributor in achieving this objective. There is a clear definition now of responsibilities and focus. The close association forged over the last decade continues. We believe that these transactions, together with their current expertise, leave Strides well positioned in their endeavours to grow their global sterile business.” Arun Kumar, Vice Chairman and Group CEO of Strides said “While the restructuring of the oncology arrangements with Aspen provides Strides greater focus and ownership of a key domain in our specialties division, we are delighted to strengthen our existing strong partnership with Aspen by entering into a licensing agreement in territories where Aspen has established distribution.” Issued by: Shauneen Beukes, Shauneen Beukes Communications Tel: +27 12 661-8467 : Cell: +27 82 389 8900 On Behalf Of: Stephen Saad, Aspen Holdings Group Chief Executive Tel: +27 31 580-8602 Gus Attridge, Aspen Holdings Deputy Group Chief Executive Tel: +27 31 580-8604 Roshni Gajjar, Aspen Investor Relations Manager Tel: +2731 580-8649; Cell: +27 82 789 1826 About Aspen Aspen, a Top 40 company listed on the Johannesburg Stock Exchange, is Africa’s largest pharmaceutical manufacturer and one of the Top 20 generics manufacturers worldwide. Aspen is a supplier of branded and generic pharmaceuticals in approximately 100 countries across the globe and of consumer and nutritional products in selected territories. Aspen has 15 pharmaceutical manufacturing facilities at 10 pharmaceutical manufacturing sites on five continents. Aspen has production capabilities for tablets, capsules, steriles, injectables, penicillins, penems, liquids, creams and infant milk formulations. For more than 150 years, Aspen has been providing high-quality, affordable products to its customers. Aspen’s has a robust pipeline of generic products which are developed under the direction of highly skilled scientists employed by Aspen and in collaboration with other global pharmaceutical research and development companies. Strides Arcolab Limited: Leadership Through Partnering Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables. The company has 14 manufacturing facilities across 6 countries, including its joint venture with Aspen in India and has a marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the company’s website at www.stridesarco.com.